Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNSPNASDAQ:DRMANASDAQ:GLTONASDAQ:IMAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$0.83+0.2%$1.06$0.77▼$200.00$4.53M2.65695,182 shs139,502 shsDRMADermata Therapeutics$0.69-1.9%$0.77$0.65▼$5.00$4.51M0.571.18 million shs132,909 shsGLTOGalecto$3.33+3.4%$2.93$2.01▼$16.07$4.26M1.3284,893 shs17,306 shsIMACIMAC$0.04+3.1%$0.04$0.75▼$1.65$26.75M-0.88708,132 shs102,556 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals+0.34%-10.56%-35.52%-77.02%-99.31%DRMADermata Therapeutics-1.91%-10.32%-16.37%-41.18%-72.01%GLTOGalecto+5.18%-1.77%+8.47%-18.88%-72.89%IMACIMAC+3.06%+6.83%+38.61%-89.78%-98.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSPCNS Pharmaceuticals2.548 of 5 stars3.35.00.00.02.20.00.6DRMADermata Therapeutics2.7862 of 5 stars3.55.00.00.02.80.80.0GLTOGalecto2.1684 of 5 stars3.52.00.00.01.10.81.3IMACIMACN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,905.53% UpsideDRMADermata Therapeutics 3.00Buy$3.00332.21% UpsideGLTOGalecto 3.00Buy$10.00200.30% UpsideIMACIMAC 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMAC, DRMA, CNSP, and GLTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.003/25/2025CNSPCNS PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/ADRMADermata TherapeuticsN/AN/AN/AN/A$0.62 per shareN/AGLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AIMACIMAC$15.22M0.08N/AN/A$0.69 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/12/2025 (Estimated)DRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-270.81%-179.96%8/6/2025 (Estimated)GLTOGalecto-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)IMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/ALatest IMAC, DRMA, CNSP, and GLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/A5/8/2025Q1 2025GLTOGalectoN/A-$1.92N/A-$1.92N/AN/A3/19/2025Q4 2024GLTOGalecto-$3.12-$5.22-$2.10-$5.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSPCNS PharmaceuticalsN/A4.944.94DRMADermata TherapeuticsN/A3.703.70GLTOGalectoN/A9.629.62IMACIMAC0.011.271.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSPCNS Pharmaceuticals14.02%DRMADermata Therapeutics8.67%GLTOGalecto14.20%IMACIMAC24.27%Insider OwnershipCompanyInsider OwnershipCNSPCNS Pharmaceuticals0.07%DRMADermata Therapeutics18.50%GLTOGalecto10.80%IMACIMAC10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableDRMADermata Therapeutics86.38 million5.20 millionNot OptionableGLTOGalecto401.32 million1.18 millionOptionableIMACIMAC10626.49 million23.84 millionNot OptionableIMAC, DRMA, CNSP, and GLTO HeadlinesRecent News About These CompaniesIMAC Holdings Issues Promissory Note for $301,000June 18 at 5:46 PM | tipranks.comRecreate the classic iMac G3 era with this cute Apple Watch chargerJune 18 at 2:14 AM | msn.comHide my wallet – this Apple Watch charger looks like the best iMac ever and has one neat design touchJune 18 at 2:14 AM | msn.comSpigen's iMac G3-Inspired Apple Watch Charger Is the Nostalgic Accessory You Didn't Know You NeededJune 17 at 7:34 AM | techtimes.comSpigen just released the Apple Watch charger stand I’ve always wantedJune 17 at 2:32 AM | 9to5mac.comWhat’s next for Mac? Here’s what I predict is coming to the Mac line-upJune 13, 2025 | msn.comApple just supercharged MacBook & iMac: Liquid Glass macOS 26 Tahoe revealed at WWDC 2025; check details hereJune 10, 2025 | fortuneindia.comIMAC Holdings Appoints New Board Members for Strategic GrowthJune 6, 2025 | tipranks.comHistory of the eMacJune 6, 2025 | msn.comIMAC Holdings Issues Promissory Note for $455,000June 5, 2025 | tipranks.comGet the Apple 2024 iMac 24-inch (M4, 10-core CPU/10-core GPU, 16GB/256GB, Green) for $1,297.06 (originally $1,499.00) – $201.94 savingsJune 4, 2025 | msn.comApple's Upcoming macOS 26 Could Be Bad News For Owners Of Older ModelsJune 4, 2025 | msn.comIt’s time for Apple to re-introduce this long discontinued macOS featureJune 2, 2025 | 9to5mac.commacOS 26 may not support these four Mac models: Is yours on the list?May 30, 2025 | msn.comWhen are new Macs coming? Here’s the latestMay 29, 2025 | 9to5mac.comRumor: macOS 26 may not support some more recent Macs including MacBook Air 2020 with Intel CPUMay 29, 2025 | tweaktown.commacOS 26 may drop support to these Intel Macs as Apple winds down transitionMay 29, 2025 | bgr.comThis Year’s ‘macOS 26’ Release May End Support for These MacsMay 29, 2025 | idropnews.comApple is reportedly dropping support for nearly every Intel Mac this yearMay 29, 2025 | msn.commacOS 26 may not support 2018 MacBook Pros, 2019 iMacs, or the iMac ProMay 29, 2025 | appleinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAC, DRMA, CNSP, and GLTO Company DescriptionsCNS Pharmaceuticals NASDAQ:CNSP$0.83 +0.00 (+0.22%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.83 0.00 (-0.22%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Dermata Therapeutics NASDAQ:DRMA$0.69 -0.01 (-1.91%) Closing price 06/18/2025 03:49 PM EasternExtended Trading$0.69 -0.01 (-1.02%) As of 06/18/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Galecto NASDAQ:GLTO$3.20 -0.03 (-0.78%) As of 06/18/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.IMAC NASDAQ:IMAC$0.04 +0.00 (+3.06%) As of 06/17/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
